• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

    6/15/23 4:01:00 PM ET
    $GILD
    $GLPG
    $JNJ
    $LIVN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GILD alert in real time by email

    Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation.

    "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong international network. Having spent three decades in the healthcare sector, he brings with him a wealth of experience and deep financial and operational know-how," said Dr. Paul Stoffels1, CEO and Chairman of Galapagos. "We are convinced that Thad's strategic and operational expertise, including in cell therapy, is an excellent fit for our company as we continue to execute on our R&D and business development strategy in our focus areas of immunology and oncology."

    Thad Huston is currently Global Head of Finance and Corporate Operations at Kite, the global leader in cell therapy. Before Kite, Thad served as CFO of LivaNova (NASDAQ:LIVN), a publicly listed medical devices company focused on neuromodulation with presence in more than 100 countries. Prior to that role, he spent over 25 years at Johnson & Johnson (J&J) (NYSE:JNJ) where he held senior financial roles at various J&J locations in the US, China, Belgium, Russia, and Hungary. During his tenure at J&J, he helped establish the R&D innovation model and played a key role in accelerating the product pipeline through focused growth strategies, investments in innovation, business development and streamlined productivity.

    "I am very excited to join Galapagos and to work with Paul and the team to realize the company's full potential," added Thad Huston. "With its growing pipeline in oncology and immunology, a European commercial infrastructure and a robust balance sheet, I strongly believe that Galapagos has the fundamentals in place to deliver on its mission to transform the lives of patients across the globe, while creating value for its stakeholders."

    This press release contains inside information within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).

    About Galapagos

    Galapagos is a fully integrated biotechnology company united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life. We focus on the key therapeutic areas of immunology and oncology, where we have developed a deep scientific expertise in multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to commercialized programs and our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. For additional information, please visit www.glpg.com or follow us on LinkedIn or Twitter.

    Contacts

    Media relations contact

    Marieke Vermeersch 

    +32 479 490 603 

    [email protected]  
    Investor relations contact 

    Sofie Van Gijsel 

    +1 781 296 1143



    Sandra Cauwenberghs 

    +32 495 58 46 63 

    [email protected]

    Forward-looking statements

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements are often, but are not always, made through the use of words or phrases such as "ongoing," "will," and "may" as well similar expressions. Forward-looking statements contained herein include, but are not limited to, statements regarding the announced leadership transition and changes in our Executive Committee and key personnel. These forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the possibility that Galapagos will encounter challenges retaining or attracting talent, that our leadership transition may be disruptive to our business operations, risks related to our ability to effectively transfer knowledge during this period of transition, and those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2022 and our subsequent filings with the SEC. The forward-looking statements contained herein are based on management's current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations, unless specifically required by law or regulation.


    1 Throughout this press release, ‘Dr. Paul Stoffels' should be read as ‘Dr. Paul Stoffels, acting via Stoffels IMC BV'

     

    Attachment

    • PR CFO COO Appointment_ENG_Final


    Primary Logo

    Get the next $GILD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GILD
    $GLPG
    $JNJ
    $LIVN

    CompanyDatePrice TargetRatingAnalyst
    Gilead Sciences Inc.
    $GILD
    4/22/2025$125.00Overweight
    Cantor Fitzgerald
    Gilead Sciences Inc.
    $GILD
    3/4/2025$115.00 → $132.00Outperform
    Oppenheimer
    LivaNova PLC
    $LIVN
    2/26/2025Outperform → Peer Perform
    Wolfe Research
    Gilead Sciences Inc.
    $GILD
    2/18/2025$120.00Hold → Buy
    Deutsche Bank
    Galapagos NV
    $GLPG
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    Gilead Sciences Inc.
    $GILD
    2/13/2025$108.00Hold → Buy
    DZ Bank
    Gilead Sciences Inc.
    $GILD
    1/10/2025$87.00 → $113.00Equal-Weight → Overweight
    Morgan Stanley
    Johnson & Johnson
    $JNJ
    12/10/2024$166.00Neutral
    BofA Securities
    More analyst ratings

    $GILD
    $GLPG
    $JNJ
    $LIVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Gilead Sciences with a new price target

      Cantor Fitzgerald resumed coverage of Gilead Sciences with a rating of Overweight and set a new price target of $125.00

      4/22/25 7:32:53 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Gilead Sciences with a new price target

      Oppenheimer reiterated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $132.00 from $115.00 previously

      3/4/25 8:15:52 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LivaNova downgraded by Wolfe Research

      Wolfe Research downgraded LivaNova from Outperform to Peer Perform

      2/26/25 7:12:54 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $GILD
    $GLPG
    $JNJ
    $LIVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)

      2/13/24 5:48:49 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    $GLPG
    $JNJ
    $LIVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Johnson & Johnson expands efforts to champion the nursing workforce globally

      New social impact platform J&J CareCommunity aims to collaboratively help address global nursing challenges Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and improve access to quality care for communities around the world. These efforts are part of J&J CareCommunity, a new social impact platform that focuses the resources and expertise of J&J and J&J Foundation to support nurses at every step of their career journey and strengthen health systems worldwide. The expansion aims to help address the global shortfall of nurses, which will reach approximately 4.5 million by 2030, driven in part by burnout and low morale, contributing to a signifi

      5/8/25 8:12:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

      Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates impact of SNIA decision and currently applicable tariffs Completed premarket approval submission for the aura6000™ System intended to treat obstructive sleep apnea Announced 12-month, top-line OSPREY data demonstrating strong response and sustained therapeutic impact for patients who received proximal hypoglossal nerve stimulation for obstructive sleep apnea LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the first quarter

      5/7/25 6:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

      Top-line results at 12 months of treatment show meaningful improvement over time: Overall responder rate of 65% Overall reduction in median apnea-hypopnea index of 68% Overall reduction in median oxygen desaturation index of 68% LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). At 12 months of therapy, the treatment arm responder rate was 65% with responders defined as those who realized at least a 50% improvement from the baseline apnea-hypopnea index (AHI) and

      5/7/25 5:45:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $GILD
    $GLPG
    $JNJ
    $LIVN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

      11/26/24 4:36:21 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

      11/26/24 4:36:21 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

      11/15/24 4:36:27 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    $GLPG
    $JNJ
    $LIVN
    Financials

    Live finance-specific insights

    See more
    • LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

      Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates impact of SNIA decision and currently applicable tariffs Completed premarket approval submission for the aura6000™ System intended to treat obstructive sleep apnea Announced 12-month, top-line OSPREY data demonstrating strong response and sustained therapeutic impact for patients who received proximal hypoglossal nerve stimulation for obstructive sleep apnea LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the first quarter

      5/7/25 6:00:00 AM ET
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Gilead Sciences Announces First Quarter 2025 Financial Results

      Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Our base business grew 4% year-over-year, primarily led by Biktarvy's continued strength, and we announced positive topline Phase 3 results for Trodelvy plus pembrolizumab in first line PD-L1+ metastatic triple negative breast cancer. With the upcoming June P

      4/24/25 4:02:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

      First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

      4/23/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GILD
    $GLPG
    $JNJ
    $LIVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders' Meeting

      Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company.  The annual report for the financial year 2024, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The annual 2024 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has the honor to invite its shareholders, holders of subscription rights, Board members, and

      3/27/25 4:01:00 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

      WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines

      3/25/25 1:11:06 PM ET
      $JNJ
      $TVGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $GILD
    $GLPG
    $JNJ
    $LIVN
    SEC Filings

    See more
    • Gilead Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/8/25 5:26:08 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 13F-HR filed by Johnson & Johnson

      13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

      5/7/25 4:47:35 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Gilead Sciences Inc.

      10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/7/25 4:32:49 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    $GLPG
    $JNJ
    $LIVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Horning Sandra was granted 1,516 shares, increasing direct ownership by 42% to 5,147 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:26:11 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Manwani Harish covered exercise/tax liability with 296 shares and was granted 1,516 shares, increasing direct ownership by 9% to 14,093 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:18:19 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Kramer Kelly A.

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:17:07 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    $GLPG
    $JNJ
    $LIVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Galapagos NV

      SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

      11/12/24 9:55:16 AM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Galapagos NV

      SC 13D/A - GALAPAGOS NV (0001421876) (Subject)

      10/8/24 4:35:06 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Galapagos NV

      SC 13D - GALAPAGOS NV (0001421876) (Subject)

      8/23/24 4:01:26 PM ET
      $GLPG
      Biotechnology: Pharmaceutical Preparations
      Health Care